JP2023539589A5 - - Google Patents
Info
- Publication number
- JP2023539589A5 JP2023539589A5 JP2023513309A JP2023513309A JP2023539589A5 JP 2023539589 A5 JP2023539589 A5 JP 2023539589A5 JP 2023513309 A JP2023513309 A JP 2023513309A JP 2023513309 A JP2023513309 A JP 2023513309A JP 2023539589 A5 JP2023539589 A5 JP 2023539589A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- egfr
- pharmaceutical composition
- composition according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069748P | 2020-08-25 | 2020-08-25 | |
| US63/069,748 | 2020-08-25 | ||
| PCT/IB2021/057794 WO2022043895A2 (en) | 2020-08-25 | 2021-08-25 | Treatment of non-small lung cancer with egfr mutations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539589A JP2023539589A (ja) | 2023-09-15 |
| JP2023539589A5 true JP2023539589A5 (cg-RX-API-DMAC10.html) | 2024-09-02 |
Family
ID=80352814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513309A Pending JP2023539589A (ja) | 2020-08-25 | 2021-08-25 | Ｅｇｆｒ変異を有する非小細胞肺がんの治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12528869B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4204455A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023539589A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230053686A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116194141A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021330539A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3192922A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL300854A (cg-RX-API-DMAC10.html) |
| JO (1) | JOP20230039A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023002362A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022043895A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230174677A1 (en) * | 2021-11-16 | 2023-06-08 | Janssen Biotech, Inc. | Use of Approved Bispecific EGFR and Met Specific Antibody Drug Product to Treat Non-Small Cell Lung Cancer (NSCLCL) |
| CN119790073A (zh) * | 2022-06-30 | 2025-04-08 | 詹森生物科技公司 | 使用抗EGFR/抗Met抗体治疗胃癌或食道癌 |
| WO2024108193A2 (en) * | 2022-11-18 | 2024-05-23 | Epibiologics, Inc. | Degradation of cmet using a bispecific binding agent |
| CN116284335A (zh) * | 2023-03-17 | 2023-06-23 | 云南中医药大学 | Egfr基因突变体的检测方法及应用 |
| WO2025158277A1 (en) * | 2024-01-22 | 2025-07-31 | Janssen Biotech, Inc. | Use of amivantamab to treat head and neck cancer |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| AU2005250484B2 (en) | 2004-06-04 | 2011-08-11 | Genentech, Inc. | EGFR mutations |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| EP3904391B1 (en) | 2010-03-10 | 2024-07-10 | Genmab A/S | Monoclonal antibodies against c-met |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| CA2832971C (en) | 2011-04-15 | 2016-04-12 | Esco Corporation | Replaceable wear parts for an earth-working roll |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| KR102373193B1 (ko) * | 2012-11-21 | 2022-03-10 | 얀센 바이오테크 인코포레이티드 | 이중특이성 EGFR/c-Met 항체 |
| US20170275367A1 (en) | 2012-11-21 | 2017-09-28 | Janssen Biotech, Inc. | Bispecific EGFR/C-Met Antibodies |
| EP3029067A1 (en) | 2014-12-01 | 2016-06-08 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific T cell-activation |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| BR112019010020A2 (pt) | 2016-11-17 | 2019-08-20 | Univ Texas | compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20 |
| WO2020102647A1 (en) | 2018-11-15 | 2020-05-22 | Invenra Inc. | Multivalent receptor-clustering agonist antibody constructs and antigen binding proteins |
| MX2021010265A (es) | 2019-02-26 | 2021-09-23 | Janssen Biotech Inc | Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos. |
| MY208668A (en) | 2019-05-14 | 2025-05-23 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors |
| IL305700A (en) | 2021-03-09 | 2023-11-01 | Janssen Biotech Inc | Treatment of cancers lacking EFGR-activating mutations |
-
2021
- 2021-08-25 EP EP21860686.1A patent/EP4204455A4/en active Pending
- 2021-08-25 JP JP2023513309A patent/JP2023539589A/ja active Pending
- 2021-08-25 KR KR1020237009896A patent/KR20230053686A/ko active Pending
- 2021-08-25 CN CN202180052496.5A patent/CN116194141A/zh active Pending
- 2021-08-25 WO PCT/IB2021/057794 patent/WO2022043895A2/en not_active Ceased
- 2021-08-25 IL IL300854A patent/IL300854A/en unknown
- 2021-08-25 US US17/411,158 patent/US12528869B2/en active Active
- 2021-08-25 CA CA3192922A patent/CA3192922A1/en active Pending
- 2021-08-25 AU AU2021330539A patent/AU2021330539A1/en active Pending
- 2021-08-25 MX MX2023002362A patent/MX2023002362A/es unknown
-
2023
- 2023-02-23 JO JOJO/P/2023/0039A patent/JOP20230039A1/ar unknown
-
2025
- 2025-11-14 US US19/389,439 patent/US20260070993A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3903828A1 (en) | Combination of antibody-drug conjugate and kinase inhibitor | |
| JP2024153659A5 (cg-RX-API-DMAC10.html) | ||
| JP2021059564A (ja) | 癌治療のための併用療法 | |
| CN101998851A (zh) | 吡铂和西妥昔单抗治疗结直肠癌的用途 | |
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| JP2023513297A5 (cg-RX-API-DMAC10.html) | ||
| US12527784B2 (en) | Combined pharmaceutical composition for treating small cell lung cancer | |
| KR20140023921A (ko) | ＥｒｂＢ 경로 저해제들에 대한 저항성을 극복하는 방법 | |
| MX2013013018A (es) | Metodo para el tratamiento oncologico combinado dirigido a egfr. | |
| JP7761490B2 (ja) | 小細胞肺がんの併用療法用キノリン誘導体 | |
| EP4464337A1 (en) | Combined use of anti-trop-2 antibody-drug conjugate and other therapeutic agents | |
| JP2025060639A (ja) | Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 | |
| WO2020249018A1 (zh) | 治疗驱动基因阳性肺癌的联用药物组合物 | |
| JP2025500784A5 (cg-RX-API-DMAC10.html) | ||
| EP3463453A1 (en) | Combination of pembrolizumab and abemaciclib for the treatment of cancer | |
| WO2025103377A1 (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| JP2022531980A5 (cg-RX-API-DMAC10.html) | ||
| CN104892763A (zh) | 抗体-药物偶联物Pertuzumab-MCC-DM1、其与Trastuzumab的组合物及其应用 | |
| US20240343807A1 (en) | Pharmaceutical composition for treating small cell lung cancer | |
| Rapidis et al. | Targeted therapies in head and neck cancer: past, present and future | |
| CN113766917A (zh) | 用于治疗头颈癌的喹啉衍生物 | |
| JP2024509920A5 (cg-RX-API-DMAC10.html) | ||
| WO2023072043A1 (zh) | 治疗肿瘤的联用药物 | |
| WO2019096233A1 (zh) | 免疫治疗剂、核苷类抗代谢物和铂类联合在制备治疗肿瘤的药物中的用途 | |
| HK40063551A (en) | Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor |